KR920700289A - 허피스바이러스 재조합 천연두바이러스 백신 - Google Patents

허피스바이러스 재조합 천연두바이러스 백신

Info

Publication number
KR920700289A
KR920700289A KR1019900702630A KR900702630A KR920700289A KR 920700289 A KR920700289 A KR 920700289A KR 1019900702630 A KR1019900702630 A KR 1019900702630A KR 900702630 A KR900702630 A KR 900702630A KR 920700289 A KR920700289 A KR 920700289A
Authority
KR
South Korea
Prior art keywords
virus
herpes
equine
smallpox
glycoprotein
Prior art date
Application number
KR1019900702630A
Other languages
English (en)
Inventor
파올레티 엔조
Original Assignee
원본미기재
헬스 리서치 인코오퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 헬스 리서치 인코오퍼레이티드 filed Critical 원본미기재
Publication of KR920700289A publication Critical patent/KR920700289A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

허피스바이러스 재조합 천연두바이러스 백신
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 재조합 왁지니아바이러스 vP425의 제조방법을 개략적으로 나타낸다,
제2도는 gp13코팅 서열을 가지고 있는 1.88Kb의 EHV－1 단편의 DNA 서열을 나타내고,
제3도는 EHV－1 gp13유전자를 재조합 왁지니아 바이러스 vP483의 제조방법을 개략적으로 나타낸다.

Claims (52)

  1. 천연두바이러스 게놈의 비필수 영역에 말 허피스바이러스의 DNA를 포함하는 것을 특징으로 하는 재조합 천연두바이러스.
  2. 제1항에 있어서, 상기 DNA가 말 허피스바이러스 당단백질을 암호화하는 것을 특징으로 하는 재조합 천연두바이러스.
  3. 제2항에 있어서, 상기 말 허피스바이러스 당단백질이 말 허피스바이러스 당단백질 gp13인 것을 특징으로 하는 재조합 천연두바이러스.
  4. 제2항에 있어서, 상기 말 허피스바이러스 당단백질이 말 허피스바이러스 당단백질 gp14인 것을 특징으로 하는 재조합 천연두바이러스.
  5. 제1항에 있어서, 상기 DNA가 2개의 말 허피스바이러스 당단백질을 암호화하는 것을 특징으로 하는 재조합 천연두바이러스.
  6. 제5항에 있어서, 상기 말 허피스바이러스 당단백질이 말 허피스바이러스 당단백질 gp13 및 말 허피스바이러스 당단백질 gp14인 것을 특징으로 하는 재조합 천연두바이러스.
  7. 제1항에 있어서, 말 허피스바이러스 당단백질이 제조됨으로써 상기 DNA가 숙주에서 발현되는 것을 특징으로 하는 재조합 천연두바이러스.
  8. 제7항에 있어서, 상기 말 허피스바이러스 당단백질이 말 허피스바이러스 당단백질 gp13인 것을 특징으로 하는 재조합 천연두바이러스.
  9. 제7항에 있어서, 상기 말 허피스바이러스 당단백질이 말 허피스바이러스 당단백질 gp14인 것을 특징으로 하는 재조합 천연두바이러스.
  10. 제1항에 있어서, 2개의 말 허피스바이러스 당단백질이 제조됨으로써 상기 DNA가 숙주에서 발현되는 것을 특징으로 하는 재조합 천연두바이러스.
  11. 제10항에 있어서, 상기 말 허피스바이러스 당단백질이 말 허피스바이러스 당단백질 gp13 말 허피스바이러스 당단백질이 gp14인 것을 특징으로 하는 재조합 천연두바이러스.
  12. 제1항에 있어서, 천연두바이러스가 왁지니아 바이러스인 것을 특징으로 하는재조합 천연두바이러스.
  13. 제1항에 있어서, 천연두바이러스가 조두 바이러스인 것을 특징으로 하는 재조합 천연두바이러스.
  14. 제13항에 있어서, 계두바이러스가 카나리아 두창 바이러스로 구성되는 군으로부터 조두 바이러스가 선택되는 것을 특징으로 하는 재조합 천연두바이러스.
  15. 제1항에 있어서, 상기 DNA가 재조합에 의해 상기 천연두바이러스에 도입되는 것을 특징으로 하는 재조합 천연두바이러스.
  16. 말 허피스바이러스 DNA 및 상기 DNA를 발현하기 위한 프로모터를 포함하는 것을 특징으로 하는 재조합 천연두바이러스.
  17. 백신으로 접종된 숙주동물에서 면역반응을 유도하기 위한, 비필수 영역에 말 허피스바이러스의 DNA를 포함하는 재조합 천연두바이러스 운반체로 구성되는 것을 특징으로 하는 백신.
  18. 제17항에 있어서, 상기 DNA가 말 허피스바이러스 당단백질을 암호화하고 발현하는 것을 특징으로 하는 백신.
  19. 제18항에 있어서, 상기 말 허피스바이러스 당단백질이 말 허피스바이러스 당단백질 gp13인 것을 특징으로 하는 백신.
  20. 제18항에 있어서, 상기 말 허피스바이러스 당단백질이 말 허피스바이러스 당단백질 gp14인 것을 특징으로 하는 백신.
  21. 제17항에 있어서, 상기 DNA가 2개의 말 허피스바이러스 당단백질을 암호화하고 발현하는 것을 특징으로 하는 백신.
  22. 제21항에 있어서, 상기 말 허피스바이러스 당단백질이 말 허피스바이러스 당단백질 gp13과 말 허피스바이러스 당단백질인 gp14인 것을 특징으로 하는 백신.
  23. 제17항에 있어서, 천연두바이러스가 왁지니아 바이러스인 것을 특징으로 하는 백신.
  24. 제17항에 있어서, 천연두바이러스가 조두 바이러스인 것을 특징으로 하는 백신.
  25. 제24항에 있어서, 계두바이러스가 카나리아 두창 바이러스인 구성되는 군으로부터 조두 바이러스가 선택되는 것을 특징으로 하는 백신.
  26. 제17항에 있어서 상기 DNA가 재조합에 의해 상기 천연두바이러스에 도입되는 것을 특징으로 하는 백신.
  27. 천연두바이러스 게놈의 비필수 영역에 허피스바이러스의 DNA를 포함하고 있는 것을 특징으로 하는 재조합 천연두바이러스.
  28. 제27항에 있어서, 상기 허피스바이러스가 알파허피스바이러스, 베타허피스바이러스 및 감마허피스바이러스로 구성되는 군으로부터 선택된 허피스바이러스 하위부류의 일원인 것을 특징으로 하는 재조합 천연두바이러스.
  29. 제28항에 있어서, 상기 허피스바이러스가 말 허피스바이러스, 위광견병 허피스바이러스, 허피스 단순바이러스, 소 허피스바이러스, 고양이 허피스바이러스, 엡스타인－바르 바이러스 및 인간 거대세포바이러스로 구성되는 군으로부터 선택되는 것을 특징으로 하는 재조합 천연두바이러스.
  30. 제27항에 있어서, 상기 DNA가 허피스바이러스 당단백질을 암화하는 것을 특징으로 하는 재조합 천연두바이러스.
  31. 제30항에 있어서, 상기 허피바이러스 당단백질이 말 허피스바이러스 gp13, 말 허피스바이러스 gp14, 말 허피스바이러스 gD, 말 허피스바이러스gp63, 말 허피스바이러스 gE, 위광견병 바이러스gp50, 위광견병 바이러스 gpⅡ, 위광견병 바이러스gpⅢ, 위광견병 바이러스gpⅠ, 허피스 단순바이러스gB, 허피스 단순바이러스gC, 허피스 단순바이러스gD, 소 허피스 단순 바이러스gI, 고양이 허피스바이러스gB, 엡스타인－바르 바이러스 gp220, 엡스타인－바르 바이러스gp340, 엡스타인－바르 바이러스gB, 엡스타인－바르 바이러스gH 및 인간 거대세포바이러스 gB로 구성되는 군으로부터 선택되는 것을 특징으로 하는 재조합 천연두바이러스.
  32. 제27항에 있어서, 상기 DNA가 최소한 2개의 허피스바이러스 당단백질을 암호화하는 것을 특징으로 하는 재조합 천연두바이러스.
  33. 제27항에 있어서, 허피스바이러스 당단백질이 제조됨으로써 상기 DNA가 숙주에서 발현되는 것을 특징으로 하는 재조합 천연두바이러스.
  34. 제33항에 있어서, 상기 말 허피바이러스 당단백질이 말 허피스바이러스gp13, 말 허피스바이러스 gp14, 말 허피스바이러스 gD, 말 허피스바이러스gp63, 말 허피스바이러스 gE, 위광견병 바이러스gp50, 위광견병 바이러스 gpⅡ, 위광견병 바이러스gpⅢ, 위광견병 바이러스gpⅠ, 허피스 단순바이러스gB, 허피스 단순바이러스gC, 허피스 단순바이러스gD, 소 허피스 단순 바이러스gI, 고양이 허피스바이러스gB, 엡스타인－바르 바이러스 gp220, 엡스타인－바르 바이러스gp340, 엡스타인－바르 바이러스gB, 엡스타인－바르 바이러스gH 및 인간 거대세포바이러스 gB로 구성되는 군으로부터 선택되는 것을 특징으로 하는 재조합 천연두바이러스.
  35. 제27항에 있어서, 최소한 2개의 허피스바이러스 당단백질이 생산됨으로써 상기 DNA가 숙주에서 발현되는 것을 특징으로 하는 재조합 천연두바이러스.
  36. 제27항에 있어서, 천연두바이러스가 왁지니아 바이러스인 것을 특징으로 하는 재조합 천여두바이러스.
  37. 제27항에 있어서, 천연두바이러스가 조두 바이러스인 것을 특징으로 하는 재조합 천여두바이러스
  38. 제37항에 있어서, 계두바이러스가 카나리아 두창 바이러스인 구성되는 군으로부터 조두 바이러스가 선택되는 것을 특징으로 하는 재조합 천여두바이러스.
  39. 제27항에 있어서, 상기 DNA가 재조합에 의하여 상기 천연두바이러스에 도입되는 것을 특징으로 하는 천연두바이러스.
  40. 허피스바이러스 DNA 및 그 DNA를 발현하기 위한 프로모터를 포함하는 것을 특징으로 하는 재조합 천연두바이러스.
  41. 백신으로 접종된 숙주동물에서 면역학적 반응을 유도하기 위한, 비필수 영역에 허피스바이러스의 DNA를 포함하는 재조합 천연두바이러스와 운반체로 구성되는 것을 특징으로 하는 백신.
  42. 제41항에 있어서, 상기 허피스바이러스가 알파허피스바이러스, 베타허피스바이러스 및 감마허피스바이러스로 구성되는 군으로부터 선택된 허피스바이러스 하위부류의 일원인 것을 특징으로 하는 백신.
  43. 제42항에 있어서, 상기 허피스바이러스가 말 허피스바이러스, 위광견병 허피스바이러스, 허피스 단순바이러스, 소 허피스바이러스, 고양이 허피스바이러스, 엡스타인－바르 바이러스 및 인간 거대세포바이러스로 구성되는 군으로부터 선택되는 것을 특징으로 하는 백신.
  44. 제41항에 있어서, 상기 DNA가 허피스바이러스 당단백질을 암호화하고 발현간하는 것을 특징으로 하는 백신.
  45. 제44항에 있어서, 상기 허피바이러스 당단백질이 말 허피스바이러스 gp13, 말 허피스바이러스 gp14, 말 허피스바이러스 gD, 말 허피스바이러스gp63, 말 허피스바이러스 gE, 위광견병 바이러스gp50, 위광견병 바이러스 gpⅡ, 위광견병 바이러스gpⅢ, 위광견병 바이러스gpⅠ, 허피스 단순바이러스gB, 허피스 단순바이러스gC, 허피스 단순바이러스gD, 소 허피스 바이러스gI, 고양이 허피스바이러스gB, 엡스타인－바르 바이러스 gp220, 엡스타인－바르 바이러스gp340, 엡스타인－바르 바이러스gB, 엡스타인－바르 바이러스gH 및 인간 거대세포바이러스 gB로 구성되는 군으로부터 선택되는 것을 특징으로 하는 백신.
  46. 제41항에 있어서, 상기 DNA가 최소한 2개의 허피바이러스 당단백질을 암호화하고 발현하는 것을 특징으로 하는 백신.
  47. 제41항에 있어서, 천연두바이러스가 왁지니아 바이러스인 것을 특징으로 하는 백신.
  48. 제41항에 있어서, 천연두바이러스가 조두 바이러스인 것을 특징으로 하는 백신.
  49. 제48항에 있어서, 계두바이러스와 카나리아 두창 바이러스로 구성되는 군으로부터 조두 바이러스가 선택되는 것을 특징으로 하는 백신.
  50. 제41항에 있어서, 상기 DNA가 재조합에 의하여 상기 천연두바이러스에 도입되는 것을 특징으로 하는 백신.
  51. 신생자손에서 모체의 면역을 회피하기 위한 방법에 있어서, 상기 방법이 천연두바이러스 게놈 비필수적 영역에 비－천연두원으로 부터의 DNA가 함유된 재조합 천연두바이러스로 신생자손을 접종하는 것으로 이루어지고, 여기에서 상기 DNA는 신생자손의 제1항원을 코드화하며 상기 항원은 신생자손의 모친에서 동일한 병원체에 대하여 면역학적 반응을 유도하기 위해 사용된 동일한 제2항원 병원체와는 다른 것임을 특징으로 하는 방법.
  52. 신생자손에서 모체의 면역성을 회피하기 위한 방법에 있어서, 상기 방법이 제1 천연두바이러스 게놈의 비필수적 영역에 비－천연두원으로 부터의 DNA가 함유된 제1재조합 천연두바이러스로 신생자손을 접종하는 것으로 이루어지고, 여기에서 상기 DNA는 신생자손의 항원 병원체를 암호화하며, 상기 제1천연두바이러스는 신생자손이 모친에서 동일한 병원체에 대한 면역학적 반응을 유도하기 위해 사용된 제2재조합 천연두바이러스와는 다른 것임을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019900702630A 1989-04-17 1990-04-16 허피스바이러스 재조합 천연두바이러스 백신 KR920700289A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33900489A 1989-04-17 1989-04-17
US339,004 1989-04-17
US39448889A 1989-08-16 1989-08-16
US394,488 1989-08-16
US07/502,834 US5338683A (en) 1981-12-24 1990-04-04 Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US502,834 1990-04-04
PCT/US1990/002094 WO1990012882A1 (en) 1989-04-17 1990-04-16 Herpes virus recombinant poxvirus vaccine

Publications (1)

Publication Number Publication Date
KR920700289A true KR920700289A (ko) 1992-02-19

Family

ID=27407304

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702630A KR920700289A (ko) 1989-04-17 1990-04-16 허피스바이러스 재조합 천연두바이러스 백신

Country Status (17)

Country Link
US (3) US5338683A (ko)
JP (2) JP3083839B2 (ko)
KR (1) KR920700289A (ko)
AT (1) AT405184B (ko)
AU (1) AU625623B2 (ko)
BE (1) BE1004369A5 (ko)
CA (1) CA2014465C (ko)
CH (1) CH682671A5 (ko)
DE (2) DE4090565T (ko)
DK (1) DK176464B1 (ko)
FR (1) FR2647808B1 (ko)
GB (1) GB2246784B (ko)
IE (1) IE61098B1 (ko)
IT (1) IT1241119B (ko)
LU (1) LU88018A1 (ko)
NL (1) NL195016C (ko)
WO (1) WO1990012882A1 (ko)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5674735A (en) * 1990-07-06 1997-10-07 University Court Of The University Of Glasgow DNA encoding the EHV-4 gH or gC glycoprotein
GB9014950D0 (en) * 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
US7374768B1 (en) * 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
BR9106879A (pt) * 1990-09-25 1993-07-20 Cantab Pharma Res Virus mutuante nao retroviral,uso do mesmo,vacina e processo de manufaturar umvirus mutante
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5759552A (en) * 1991-03-07 1998-06-02 Virogenetics Corporation Marek's disease virus recombinant poxvirus vaccine
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
ATE181108T1 (de) * 1991-08-26 1999-06-15 Immuno Ag Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
EP0538496B1 (en) * 1991-08-26 2003-10-29 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
US5869312A (en) * 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
CA2156423A1 (en) * 1993-02-26 1994-09-01 Mark D. Cochran Recombinant fowlpox viruses and uses thereof
US6010703A (en) * 1993-07-26 2000-01-04 Board Of Trustees Operating Michigan State University Recombinant poxvirus vaccine against feline rhinotracheitis
DE69535561T2 (de) * 1994-03-30 2008-06-05 Connaught Technology Corp., Greenville NUKLEOTID- UND AMINOSÄURESEQUENZEN gB, gC UND gD DES HERPESVIRUS DES HUNDES UND IHRE VERWENDUNGEN
EP0758397B1 (en) * 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
US6183752B1 (en) * 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
CA2321161C (en) 1998-02-24 2011-12-20 Andrew D. Weinberg Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
WO1999043839A1 (en) 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
CA2359075A1 (en) 1999-02-19 2000-08-24 Michigan State University An antigen test to detect equine protozoal myeloencephalitis in horse serum and cerebrospinal fluid
WO2000051432A1 (en) 1999-03-03 2000-09-08 The Trustees Of The University Of Pennsylvania Vaccines and gene therapy compositions and methods of making and using the same
BR0010155A (pt) * 1999-04-30 2002-01-15 Univ Pennsylvania Proteìnas isolada, e quimérica, composição, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição de vacina recombinante ou composição de vacina atenuada, composição farmacêutica, métodos de imunizar um indivìduo contra um imunógeno, proteìna não-cd80 isolada, molécula de ácido nucleico, e, método de imunossuprimir um indivìduo
WO2000076538A1 (en) 1999-06-10 2000-12-21 Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
CZ20014392A3 (cs) * 1999-06-10 2002-06-12 Merial Vakcína AND pro domácí a sportovní zvířata
AU7108700A (en) 1999-09-02 2001-03-26 Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
US7419668B1 (en) 1999-09-02 2008-09-02 Board Of Trustees Of Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
PT1248646E (pt) * 1999-12-21 2008-03-19 Merial Sas Composições e vacinas contendo antigénio(s) de cryptosporidium parvum e de outro patógeno entérico
ATE398188T1 (de) * 2000-07-14 2008-07-15 Univ Pennsylvania Für akzessorische hiv proteine kodierende dna impfstoffe
CN1549730A (zh) * 2000-10-04 2004-11-24 ���������Ǵ�ѧ�й��� 黄病毒和瘟病毒衣壳蛋白的组成和使用方法
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
AU2002231639B2 (en) * 2000-11-23 2007-01-04 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US20020108132A1 (en) * 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
WO2002079447A2 (en) 2001-03-30 2002-10-10 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) * 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
US7176300B2 (en) * 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
US8216585B2 (en) 2001-05-25 2012-07-10 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US7550650B2 (en) * 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7294507B2 (en) * 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US20100333219A1 (en) * 2001-11-30 2010-12-30 Synageva Biopharma Corp. Methods of protein production using ovomucoid regulatory regions
US7335761B2 (en) * 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
US20040241723A1 (en) * 2002-03-18 2004-12-02 Marquess Foley Leigh Shaw Systems and methods for improving protein and milk production of dairy herds
NZ536592A (en) * 2002-04-19 2007-01-26 Bavarian Nordic As Modified vaccinia virus ankara for the vaccination of neonates
NZ536502A (en) * 2002-05-16 2005-10-28 Bavarian Nordic As Recombinant poxvirus expressing homologous genes inserted into the poxviral genome for inducing an immune response in a mammal
CN1692156B (zh) * 2002-09-05 2011-05-11 巴法里安诺迪克有限公司 在无血清条件下培养原代细胞和扩增病毒的方法
JP2006509526A (ja) * 2002-12-13 2006-03-23 アヴェンティス パストゥール インコーポレイテッド トリ胚性幹細胞上におけるａｌｖａｃの産生
CN1980571A (zh) * 2003-01-24 2007-06-13 阿维季尼克斯股份有限公司 禽类及禽蛋中表达的外源蛋白质
US7262027B2 (en) * 2003-03-14 2007-08-28 Medical College Of Ohio Polypeptide and DNA immunization against Coccidioides spp. infections
EP2390352A1 (en) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
ATE535249T1 (de) 2003-06-13 2011-12-15 Univ Pennsylvania Vakzine, immuntherapeutika und verfahren zu ihrer verwendung
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
ES2417019T3 (es) 2003-11-13 2013-08-05 University Of Georgia Research Foundation, Inc. Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa
JP2007525217A (ja) 2004-02-19 2007-09-06 ザ ガバナーズ オブ ザ ユニバーシティー オブ アルバータ レプチンプロモーター多型及びその使用
US20080274140A1 (en) 2004-11-19 2008-11-06 David B Weiner Vaccines and Methods for Using the Same
CN101223187A (zh) * 2004-11-24 2008-07-16 萨拉普托斯股份公司 用作双重胱天蛋白酶-2/-6抑制剂的新肽及其生物学应用
CN101208104B (zh) 2005-04-25 2012-10-31 梅瑞尔有限公司 Nipah病毒疫苗
CA2617341C (en) * 2005-07-28 2011-03-29 Pfizer Products Inc. Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
JP2009515529A (ja) 2005-11-14 2009-04-16 メリアル リミテッド 腎不全のための遺伝子療法
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7745158B2 (en) * 2005-12-14 2010-06-29 Kimberly-Clark Worldwide, Inc. Detection of secreted aspartyl proteases from Candida species
ATE533782T1 (de) 2006-01-13 2011-12-15 Univ Pennsylvania Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
EP3167900B1 (en) 2006-03-29 2018-11-21 Merial Limited Vaccine against streptococci
WO2007136763A2 (en) * 2006-05-19 2007-11-29 Sanofi Pasteur, Inc. Immunological composition
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
JP2009544333A (ja) 2006-07-28 2009-12-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改良されたワクチンおよびそれを使用するための方法
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
AU2007345347B2 (en) 2007-01-26 2013-11-07 Synageva Biopharma Corp Transgene expression in avians
DK2147105T3 (da) 2007-05-02 2013-06-03 Merial Ltd Dna-plasmider med forbedret ekspression og stabilitet
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
US20090246226A1 (en) * 2008-03-28 2009-10-01 Zeon Corporation Avian vaccines possessing a positive marker gene
KR101652767B1 (ko) 2008-04-04 2016-08-31 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-28을 이용한 백신 및 면역치료제, 및 그를 사용하는 방법 및 조성물
CA2720166A1 (en) * 2008-04-04 2009-10-08 David B. Weiner Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
ES2760004T3 (es) 2008-05-08 2020-05-12 Boehringer Ingelheim Animal Health Usa Inc Vacuna contra Leishmania utilizando un inmunnógeno salival de mosca de la arena
KR101609233B1 (ko) 2008-10-29 2016-04-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개량된 ｈｃｖ 백신 및 이를 이용하는 방법
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US9050287B2 (en) 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
US20100192236A1 (en) * 2009-01-28 2010-07-29 University Of South Carolina Modulation of Delta Opioid Receptor Expression
EP2414386B1 (en) 2009-04-03 2016-01-27 Merial Limited Newcastle disease virus vectored avian vaccines
US20100284977A1 (en) * 2009-04-28 2010-11-11 University Of South Carolina Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters
EP2424999A1 (en) 2009-04-30 2012-03-07 Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) Modified immunization vectors
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
CN102821790A (zh) 2009-09-14 2012-12-12 宾夕法尼亚大学托管会 包含IL-15受体α和/或编码IL-15受体α的核酸分子的疫苗和免疫治疗剂,以及其使用方法
IN2012DN03928A (ko) 2009-11-02 2015-09-04 Univ Pennsylvania
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CN102781952B (zh) 2010-02-08 2015-09-02 宾夕法尼亚大学托管会 编码rantes的核酸分子、包含其的组合物以及其使用方法
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
MX346784B (es) 2010-11-12 2017-03-31 Inovio Pharmaceuticals Inc Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
EA033467B1 (ru) 2011-01-31 2019-10-31 Univ Pennsylvania Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
EP3760227A1 (en) 2011-02-11 2021-01-06 The Trustees of the University of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
AU2012240240A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
US20140287931A1 (en) 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CA2834288A1 (en) 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
ES2758713T3 (es) 2011-07-11 2020-05-06 Inovio Pharmaceuticals Inc Vacuna de ADN contra el virus de Lassa
CN103957932B (zh) 2011-07-20 2017-06-23 梅里亚有限公司 包含最优化的猫白血病病毒包膜基因的重组猫白血病病毒疫苗
SI2741740T1 (sl) 2011-08-12 2017-08-31 Merial, Inc. Vakuumsko konzerviranje bioloških proizvodov, zlasti cepiv
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
WO2013055326A2 (en) 2011-10-12 2013-04-18 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
WO2013062507A1 (en) 2011-10-24 2013-05-02 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
KR102101819B1 (ko) 2011-12-12 2020-04-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
CA2858884A1 (en) 2011-12-12 2013-06-20 The Trustees Of The University Of Pennsylvania Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
AU2013235423B2 (en) * 2012-03-20 2017-03-30 Boehringer Ingelheim Animal Health USA Inc. Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein C and uses thereof
JP2015514132A (ja) 2012-04-10 2015-05-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒト呼吸器合胞体ウイルスコンセンサス抗原、核酸構築物、およびそれらから作製されるワクチン、ならびにその使用方法
MX360137B (es) 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
EP2968514A1 (en) 2013-03-12 2016-01-20 Merial, Inc. Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
CN114181961A (zh) 2013-03-12 2022-03-15 宾夕法尼亚大学理事会 用于人乳头状瘤病毒的改进疫苗及其使用方法
JP6817062B2 (ja) 2013-03-15 2021-01-20 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 蹄疫ウイルス（ｆｍｄｖ）コンセンサスタンパク質、そのコード配列、およびそれから作成されるワクチン
EP3607974A1 (en) 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Cancer vaccines and methods of treatment using the same
EP3125932A1 (en) 2014-04-03 2017-02-08 Boehringer Ingelheim Vetmedica, Inc. Porcine epidemic diarrhea virus vaccine
EP3215188A1 (en) 2014-11-03 2017-09-13 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
AU2016282772B2 (en) 2015-06-23 2019-09-05 Boehringer Ingelheim Animal Health USA Inc. PRRSV minor protein-containing recombinant viral vectors and methods of making and use thereof
PL3344289T3 (pl) 2015-08-31 2021-01-11 Boehringer Ingelheim Vetmedica Gmbh Szczepionki Pestiwirusowe na drżenia wrodzone
AU2016323106A1 (en) 2015-09-16 2018-03-29 Boehringer Ingelheim Animal Health USA Inc. Salmonella Choleraesuis-Salmonella Typhimurium vaccines
NZ751014A (en) 2016-09-20 2023-03-31 Boehringer Ingelheim Vetmedica Gmbh New ehv insertion site orf70
CA3036386A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
AR109538A1 (es) 2016-09-20 2018-12-19 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra la gripe porcina
EP3516064A1 (en) 2016-09-20 2019-07-31 Boehringer Ingelheim Vetmedica GmbH New promoters
UA127859C2 (uk) 2016-11-03 2024-01-31 Бьорінгер Інгельхайм Ветмедіка Гмбх Вакцина проти свинячого парвовірусу
HUE061972T2 (hu) 2016-11-03 2024-02-28 Boehringer Ingelheim Vetmedica Gmbh Vakcina sertés parvovirus és sertés reprodukciós és légzõszervi szindróma vírus ellen, és eljárások ezek elõállítására
EA201991762A1 (ru) 2017-01-30 2020-01-23 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Вакцины против коронавируса свиней
BR112020000711A2 (pt) 2017-07-12 2020-07-14 Boehringer Ingelheim Animal Health USA Inc. composições imunogênicas de senecavírus a e métodos destas
MY201967A (en) 2017-09-23 2024-03-27 Boehringer Ingelheim Pharma Paramyxoviridae expression system
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
DK3737397T3 (da) 2017-12-13 2023-02-20 Inovio Pharmaceuticals Inc Cancervacciner mod PRAME og anvendelse deraf
KR20230116957A (ko) 2017-12-13 2023-08-04 이노비오 파마수티컬즈, 인크. Muc16을 표적화하는 암 백신 및 이의 용도
BR112020010499A2 (pt) 2017-12-13 2020-11-24 Inovio Pharmaceuticals, Inc. vacinas de câncer de alvo de mesotelina e usos das mesmas
RU2711907C2 (ru) * 2017-12-22 2020-01-23 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Рекомбинантный белок, содержащий антигенно-значимые фрагменты белков вируса гепатита Е, используемый в тест-системах для серодиагностики гепатита Е (варианты)
US11033616B2 (en) 2018-02-23 2021-06-15 Boehringer Ingelheim Vetmedica Gmbh Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
AU2019239562A1 (en) 2018-03-19 2020-08-13 Boehringer Ingelheim Vetmedica Gmbh New EHV with inactivated UL18 and/or UL8
AU2019239552A1 (en) 2018-03-19 2020-09-10 Boehringer Ingelheim Vetmedica Gmbh EHV insertion site UL43
EA202092216A1 (ru) 2018-03-26 2021-06-11 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Способ получения иммуногенной композиции
EP3852800A1 (en) 2018-09-20 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Intranasal vector vaccine against porcine epidemic diarrhea
CN112867505A (zh) 2018-09-20 2021-05-28 勃林格殷格翰动物保健有限公司 经修饰的pedv刺突蛋白
CN115768784A (zh) 2020-02-06 2023-03-07 勃林格殷格翰动物保健有限公司 用于检测抗弹状病毒抗体的多肽
AU2021356630A1 (en) 2020-10-05 2023-06-08 Boehringer Ingelheim Vetmedica Gmbh Fusion protein useful for vaccination against rotavirus
US20220160864A1 (en) 2020-10-05 2022-05-26 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
US20240050555A1 (en) 2022-04-05 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061898A (en) 1963-03-07 1967-03-15 Philips Electronic Pharma Method for protecting dogs against canine distemper
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
AU570940B2 (en) * 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes
EP0162738A1 (en) 1984-04-09 1985-11-27 MOLECULAR GENETICS RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP Production of pseudorabies virus subunit vaccines
US5242829A (en) * 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
EP0261940A3 (en) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies vaccines and dna vectors for recombination with pox viruses
DE3853088T2 (de) * 1987-03-27 1995-10-19 Nippon Zeon Co Rekombinantes Avipoxvirus.
EP0297924A3 (en) * 1987-07-01 1990-07-11 City Of Hope Recombinant vaccinia virus expressing hsv 1 gb
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1990001546A1 (en) * 1988-08-05 1990-02-22 Applied Biotechnology, Inc. Equine herpesvirus-1 vaccine
IE68404B1 (en) 1990-11-20 1996-06-12 Virogenetics Corp Measles virus recombinant poxvirus vaccine

Also Published As

Publication number Publication date
CA2014465A1 (en) 1990-10-17
JP2000157292A (ja) 2000-06-13
DK176464B1 (da) 2008-03-31
JP3083839B2 (ja) 2000-09-04
GB2246784B (en) 1993-04-28
AU5552090A (en) 1990-11-16
GB2246784A (en) 1992-02-12
BE1004369A5 (fr) 1992-11-10
GB9120655D0 (en) 1991-11-27
DK174391A (da) 1991-12-12
IE61098B1 (en) 1994-09-21
AU625623B2 (en) 1992-07-16
AT405184B (de) 1999-06-25
DE4090565C2 (de) 2000-03-09
DK174391D0 (da) 1991-10-15
NL9020677A (nl) 1992-02-03
NL195016C (nl) 2003-06-10
ATA902590A (de) 1998-10-15
DE4090565T (ko) 1992-05-14
IE901380L (en) 1990-10-17
US6183750B1 (en) 2001-02-06
LU88018A1 (fr) 1992-03-11
CA2014465C (en) 1999-06-15
IT9020063A1 (it) 1991-10-17
WO1990012882A1 (en) 1990-11-01
IT1241119B (it) 1993-12-29
CH682671A5 (fr) 1993-10-29
US5338683A (en) 1994-08-16
US5482713A (en) 1996-01-09
JPH04505248A (ja) 1992-09-17
JP3246735B2 (ja) 2002-01-15
FR2647808B1 (fr) 1995-03-03
FR2647808A1 (fr) 1990-12-07
IT9020063A0 (it) 1990-04-17

Similar Documents

Publication Publication Date Title
KR920700289A (ko) 허피스바이러스 재조합 천연두바이러스 백신
Zuckermann et al. Complex between glycoproteins gI and gp63 of pseudorabies virus: its effect on virus replication
Studdert et al. Differentiation of respiratory and abortigenic isolates of equine herpesvirus 1 by restriction endonucleases
KR890701757A (ko) 재조합 아비폭스 바이러스
GEP20084431B (en) Papilloma virus vaccine
EP0261940A3 (en) Pseudorabies vaccines and dna vectors for recombination with pox viruses
PT81367B (pt) Processo para produzir vacinas orais usando adenovirus como vector
FR2602791B1 (fr) Procede de culture du virus de la rhinotracheite infectieuse de la dinde, et vaccin prepare a partir du virus ainsi obtenu
Plummer et al. Equine herpesviruses: antigenic relationships and deoxyribonucleic acid densities
Pay et al. Production of rabies vaccine by an industrial scale BHK 21 suspension cell culture process
DE69132417D1 (de) Impfstoff gegen die Lyme-Krankheit
BR9303226A (pt) Processo e vacina para produzir anticorpos ou imundade mediada por celulas e adenovirus recombinante
ATE73349T1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
DE3888290D1 (de) Mutanten des infektiösen bovinen Rhinotracheitisvirus, Vakzine die sie enthalten, Verfahren zu ihrer Herstellung und ihrer Verwendung.
CA2011896A1 (en) Ringworm vaccine
Cook et al. Protection against lethal equine herpes virus type 1 (subtype 1) infection in hamsters by immune stimulating complexes (ISCOMs) containing the major viral glycoproteins
ES8105930A1 (es) Procedimiento para la preparacion de vacunas de virus poli- valentes
Sheppard Viral vectors for veterinary vaccines
Love et al. Characterization of the glycoprotein D gene products of equine herpesvirus 1 using a prokaryotic cell expression vector
KR20230050444A (ko) 공동-자극 분자를 발현하는 재조합 폭스비리대 벡터
ATE173760T1 (de) Verfahren zur herstellung von lebenden zellkulturen, die durch einen multiple sklerose assoziierten virus infiziert sind
ZA874434B (en) Varicella-zoster virus as a live recombinant vaccine
Blue et al. Antigenic relationships among four herpesviruses
DK200701150A (da) Rekombinant poxvirus og vaccine mod herpesvirus indeholdende dette
Limcumpao Restriction endonuclease analysis of canine herpesviruses isolated in Japan.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid